Journament

Keyword Connections - depressive disorder Keywords

Connection Type	Connection
Journals	Journal of affective disorders The Cochrane database of systematic reviews l'encephale cns drugs
Research Groups	No Research Group Connected
Bibliographies	[1] [Management of child and adolescent depression in primary care: A systematic meta-review]. [2] Prevalence of Childhood Affective disorders in Turkey: An epidemiological study. [3] Predictors of cognitive remediation therapy improvement in (partially) remitted unipolar depression. [4] Pharmacological interventions for treatment-resistant depression in adults. [5] Prescription of Valproate-Containing Medicines in Women of Childbearing Potential who have Psychiatric Disorders: Is It Worth the Risk? [6] relationship between depressive symptoms and mirna expression level in monocytes of patients with depression before and after antidepressant treatment [7] Relationship of cognitive impairment with depressive symptoms and psychosocial function in patients with major depressive disorder: Cross-sectional analysis of baseline data from PERFORM-J. [8] Sex-specific plasma metabolome signatures in major depressive disorder. [9] The paradox of relaxation training: Relaxation induced anxiety and mediation effects of negative contrast sensitivity in generalized anxiety disorder and major depressive disorder. [10] Association of thyroid dysfunction with suicide attempts in first-episode and drug naïve patients with major depressive disorder. [11] A genome-wide association meta-analysis of prognostic outcomes following cognitive behavioural therapy in individuals with anxiety and depressive disorders [12] Depressive disorder and Austim Spectrum Disorder: Scoping review since DSM-5 publication [13] Ratio of plasma BDNF to leptin levels are associated with treatment response in major depressive disorder but not in panic disorder: A 12-week follow-up study. [14] An Online Mindfulness-Based Cognitive Behavioral Therapy Intervention for Youth Diagnosed With Major Depressive Disorders: Protocol for a Randomized Controlled Trial. [15] White matter disturbances in major depressive disorder: a coordinated analysis across 20 international cohorts in the ENIGMA MDD working group. [16] Comorbidity with more anxiety disorders associated with a poorer prognosis persisting at the 10-year follow-up among patients with major depressive disorder. [17] Prevalence and recognition of depressive disorders among Chinese older adults receiving primary care: A multi-center cross-sectional study. [18] Major depressive disorder in children and adolescents. [19] Abnormal functional connectivity strength in first-episode, drug-naïve adult patients with major depressive disorder. [20] Investigating executive control network and default mode network dysfunction in major depressive disorder. [21] Blame-rebalance fMRI neurofeedback in major depressive disorder: A randomised proof-of-concept trial. [22] Natural health products, dietary minerals and over-the-counter medications as add-on therapies to antidepressants in the treatment of major depressive disorder: a review. [23] Comparative efficacy and safety of L. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials. [24] Crocus sativus L. versus Citalopram in the Treatment of Major Depressive Disorder with Anxious Distress: A Double-Blind, Controlled Clinical Trial. [25] Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: a randomized, double-blind, placebo-controlled, pilot clinical trial. [26] Comparative efficacy and safety of Crocus sativus L. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials [27] Art as a Therapeutic Tool in Depressive Disorders: a Systematic Review of the Literature. [28] Using text mining to extract depressive symptoms and to validate the diagnosis of major depressive disorder from electronic health records. [29] Altered dynamic functional connectivity in weakly-connected state in major depressive disorder. [30] Insulin sensitivity, proinflammatory markers and adiponectin in young males with different subtypes of depressive disorder. [31] Indices of insulin resistance and glucotoxicity are not associated with bipolar disorder or major depressive disorder, but are differently associated with inflammatory, oxidative and nitrosative biomarkers. [32] C-reactive protein: A differential biomarker for major depressive disorder and bipolar II disorder. [33] Amygdala astrocyte reduction in subjects with major depressive disorder but not bipolar disorder [34] Cognition in older adults with bipolar disorder versus major depressive disorder [35] Novel markers of inflammation and their relevance to depression: The unique relation of the Neutrophil: Lymphocyte Ratio (NLR) and the Cortisol:C-reactive protein (CORT/CRP) ratio to an intermediate phenotype of Major Depressive Disorders (MDD) [36] An overview of the heterogeneity of major depressive disorder: Current knowledge and Future prospective. [37] The Cost-Effectiveness of Cognitive Behavioral Therapy Versus Second-Generation Antidepressants for Initial Treatment of Major Depressive Disorder in the United States: A Decision Analytic Model. [38] The Relationship Between Smoking and Suicidal Behavior in Psychiatric Patients with Major Depressive Disorder [39] Adverse childhood experiences and alexithymia in patients with major depressive disorder. [40] Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. [41] Double Blinded Randomized Trial of Subcutaneous Trigeminal Nerve Stimulation as Adjuvant Treatment for Major Unipolar Depressive Disorder [42] Quantifying the level of difficulty to treat major depressive disorder with antidepressants: Treatment Resistance to Antidepressants Evaluation Scale. [43] Overeating and food addiction in Major Depressive Disorder: Links to peripheral dopamine. [44] [A pilot study of transcranial alternating current stimulation in the treatment of drug-naive adult patients with major depressive disorder]. [45] The Influence of Pharmacodynamic Genes on Fluoxetine Response in Pediatric Anxiety and Depressive Disorders. [46] Sex differences on the relation between major depressive disorder and labor market outcomes: A national prospective study. [47] Decreased plasma glial cell line-derived neurotrophic factor level in major depressive disorder is associated with age and clinical severity. [48] Impact of Cognitive Symptoms on Health-Related Quality of Life and Work Productivity in Chinese Patients with Major Depressive Disorder: Results from the PROACT Study. [49] Major Depressive Disorder Is Associated With Cardiovascular Risk Factors and Low Omega-3 Index [50] Randomized, Double-Blind, Placebo-Controlled Trial of the mGlu2/3 Negative Allosteric Modulator Decoglurant in Partially Refractory Major Depressive Disorder [51] Review of Maintenance Trials for Major Depressive Disorder: A 25-Year Perspective From the US Food and Drug Administration [52] Major Depressive Disorder Predicts Completion, Adherence, and Outcomes in Cardiac Rehabilitation: A Prospective Cohort Study of 195 Patients With Coronary Artery Disease [53] Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity [54] Failure Rate and “Professional Subjects” in Clinical Trials of Major Depressive Disorder [55] Reply to Failure Rate and “Professional Subjects” in Clinical Trials of Major Depressive Disorder [56] Report by the ACNP Task Force on response and remission in major depressive disorder [57] Procognitive Effects of Antidepressants and Other Therapeutic Agents in Major Depressive Disorder: A Systematic Review [58] Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder [59] Duloxetine, 60 mg Once Daily, for Major Depressive Disorder: A Randomized Double-Blind Placebo-Controlled Trial [60] genome-wide analysis in uk biobank identifies four loci associated with mood instability and genetic correlation with major depressive disorder, anxiety disorder and schizophrenia [61] psychosocial interventions in depressive disorders [62] features of cognitive dysfunction in patients with depressive disorder and cerebrovascular pathology [63] brain-derived neurotrophic factor and major depressive disorder: evidence from meta-analyses [64] cost-effectiveness of collaborative care including pst and an antidepressant treatment algorithm for the treatment of major depressive disorder in primary care; a randomised clinical trial [65] psychostimulants in the treatment of depressive disorders [66] features of pathomorphosis of endogenous depressive disorders [67] symptom severity, affective and somatic symptom clusters predict poorer social cognition performance in current but not remitted major depressive disorder [68] t cell phenotype and t cell receptor repertoire in patients with major depressive disorder [69] psychiatric manifestations of sporadic creutzfeldt-jakob disease simulate depressive disorder with psychotic symptoms [70] coexisting fibromyalgia, depressive disorder, and tension headache: chance finding or common pathology? [71] p300 latency as an indicator of severity in major depressive disorder [72] improvement in the approaches to the treatment of emigrants and re-emigrants with depressive disorders [73] does duloxetine improve cognitive function independently of its antidepressant effect in patients with major depressive disorder and subjective reports of cognitive dysfunction? [74] anti-n-methyl-d-aspartate receptor encephalitis causing a prolonged depressive disorder evolving to inflammatory brain disease [75] a review of the role of social cognition in major depressive disorder [76] major depressive disorder with melancholia displays robust alterations in resting state heart rate and its variability: implications for future morbidity and mortality [77] analysis of the association of mir124-1 and its target gene rgs4 polymorphisms with major depressive disorder and antidepressant response [78] changes of grey matter volume in first-episode drug-naive adult major depressive disorder patients with different age-onset [79] exercise leads to better clinical outcomes in those receiving medication plus cognitive behavioral therapy for major depressive disorder [80] c-quality: cost and quality-of-life pharmacoeconomic analysis of antidepressants used in major depressive disorder in the regional italian settings of veneto and sardinia [81] neural activity during interoceptive awareness and its associations with alexithymia – an fmri study in major depressive disorder and non-psychiatric controls [82] pattern separation: a potential marker of impaired hippocampal adult neurogenesis in major depressive disorder [83] formulating a return-to-work decision for employees with major depressive disorders: occupational therapists’ experiences [84] desvenlafaxine in the treatment of major depressive disorder [85] depression reduces accuracy while parkinsonism slows response time for processing positive feedback in patients with parkinson’s disease with comorbid major depressive disorder tested on a probabilistic category-learning task [86] preventive effect of liothyronine on electroconvulsive therapy-induced memory deficit in patients with major depressive disorder: a double-blind controlled clinical trial [87] effect of an educational booklet on knowledge and attitude regarding major depressive disorder in medical students in delhi [88] abnormal white matter integrity in chinese young adults with first-episode medication-free anxious depression: a possible neurological biomarker of subtype major depressive disorder [89] reduced fractional anisotropy in patients with major depressive disorder and associations with vascular stiffness [90] Meta-analysis of Plasma Interleukine-6 Levels in Patients with Depressive Disorder [91] Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset [92] Duloxetine Efficacy for Major Depressive Disorder in Male vs. Female Patients: Data From 7 Randomized, Double-Blind, Placebo-Controlled Trials [93] Quality of life and subjective sleep-related measures in bipolar disorder and major depressive disorder. [94] Major Depressive Disorder Predicts Completion, Adherence, and Outcomes in Cardiac Rehabilitation: A Prospective Cohort Study of 195 Patients With Coronary Artery Disease [95] Prediction of Probable Major Depressive Disorder in the Taiwan Biobank: An Integrated Machine Learning and Genome-Wide Analysis Approach [96] An 8-Week, Open-Label Trial of Duloxetine for Comorbid Major Depressive Disorder and Chronic Headache [97] A Double-Blind, Randomized, Placebo-Controlled Clinical Trial of S-Adenosyl-l-Methionine (SAMe) Versus Escitalopram in Major Depressive Disorder [98] Long-Term Outcome of Major Depressive Disorder in Psychiatric Patients Is Variable [99] Long-term Efficacy and Tolerability of Adjunctive Aripiprazole for Major Depressive Disorder: Systematic Review and Meta-analysis [100] Depressive disorders among children in the transforming China: an epidemiological survey of prevalence, correlates, and service use. [101] Plasma alpha-trypsin inhibitor heavy chain 4 as an age-specific biomarker in the diagnosis and treatment of major depressive disorder.